Log in
Enquire now
‌

US Patent 11999753 Tetrahydropyridopyrimidine pan-KRas inhibitors

Patent 11999753 was granted and assigned to Mirati Therapeutics on June, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Patent abstract

The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11999753 Tetrahydropyridopyrimidine pan-KRas inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo